Drug Overview

Darinaparsin is an investigational cancer drug designed to target tumor cells with a novel arsenic‑based structure. It shows promise in treating certain blood cancers and some solid tumors, particularly in patients who have not responded well to standard therapies. Unlike older arsenic compounds, darinaparsin is an organic arsenical derivative of glutathione, which may provide better tolerability while still using arsenic in a controlled way to attack cancer cells.

Because it is not yet FDA‑approved, darinaparsin is used only in clinical trials or under special regulatory designations, not as a routine treatment. It is usually given as an intravenous (IV) infusion, although oral forms are also being studied.

Generic Name: Darinaparsin.
US Brand Names: Darvias, Zinapar (trade names used in some regions, not yet standard commercial brands in the U.S.).
Drug Class: Organic arsenical compound (arsenic‑containing derivative of glutathione).
Route of Administration: Intravenous (IV) infusion; oral formulations studied in trials.
FDA Approval Status: Not FDA‑approved; investigational drug with orphan drug designation for specific lymphomas in the United States and Europe.

What Is It and How Does It Work? (Mechanism of Action)

Darinaparsin works as a “smart” arsenic‑based agent by attacking cancer cells at the molecular level, rather than killing all fast‑growing cells broadly like traditional chemotherapy. Its main target is the mitochondria, the energy‑producing centers inside cells. In cancer cells, darinaparsin accumulates and disrupts mitochondrial function, leading to energy failure and stress inside the tumor cell.

The drug also increases reactive oxygen species (ROS), which are highly reactive molecules that damage proteins, DNA, and lipids inside the cell. This oxidative stress triggers cell‑cycle arrest, particularly at the G2/M checkpoint, stopping division and allowing the cell time to either repair itself or undergo cell death. At the same time, darinaparsin modulates key signal‑transduction pathways, including stress‑response and survival pathways, which can tilt the balance away from continued growth.

A unique feature of darinaparsin is its interaction with glutathione and related pathways. Many cancer cells use high levels of glutathione to protect themselves from toxins and oxidative stress. Darinaparsin binds to and alters glutathione‑related proteins, reducing this protective shield. This makes cancer cells more vulnerable and leads to apoptosis (programmed cell death), often with relative sparing of most healthy cells.

Because darinaparsin uses a targeted arsenic mechanism instead of a broad‑spectrum effect, it is considered a novel “arisen‑drug” strategy, aiming to harness the known anticancer activity of arsenic while improving safety.

FDA-Approved Clinical Indications

Darinaparsin is not currently FDA‑approved for any routine clinical use. It holds orphan drug status for specific lymphomas, which means regulators recognize its potential in rare cancers even though formal approval has not yet been granted.

Oncological uses (investigational)

Relapsed or refractory peripheral T‑cell lymphoma (PTCL), where standard treatments have failed or stopped working.
Other hematologic cancers, including certain cases of multiple myeloma, are under early‑phase or exploratory trials.
Solid tumors, such as liver cancer, where researchers are testing darinaparsin either alone or combined with other therapies.

These uses are still experimental and are defined by clinical‑trial protocols rather than standard treatment guidelines.

Non‑oncological uses (if any)

There are currently no identified non‑cancer (non‑oncological) uses for darinaparsin. Its development and regulatory focus are entirely on cancer treatment, particularly in rare or difficult‑to‑treat malignancies.

Dosage and Administration Protocols

Darinaparsin is given mainly as an intravenous infusion in clinical trials. Doses and schedules can vary by protocol, cancer type, and patient tolerance. Below is a simplified, readable summary of typical investigational dosing.

Feature	Description
Patient group (adults with PTCL or solid tumors)	300 mg/m² (maximum tolerated dose in Phase II trials).
Frequency of administration	Once daily, over several days per treatment cycle.
Infusion time	Typically, around 1–2 hours per dose, consistent with standard IV chemotherapy timing.
Higher dose range studied	420–588 mg/m² once daily, multiple days, used in dose‑finding studies; associated with dose‑limiting neurotoxicity and not considered routine.
Oral formulation (investigational)	Not yet established; tested in Phase I settings for solid tumors with daily dosing and no fixed standard schedule.

Because darinaparsin is investigational, there is no well‑established, widely published dose‑adjustment guideline for kidney or liver problems. Clinicians and trial teams may reduce the dose, delay cycles, or stop treatment if patients show neurotoxicity, low blood counts, or signs of severe organ stress. Patients should always follow the specific dosing and scheduling instructions given in the clinical‑trial protocol and should not change the dose or timing without medical advice.

Clinical Efficacy and Research Results

Darinaparsin has been studied in clinical trials mainly from 2020 to 2025, focusing on relapsed or refractory peripheral T‑cell lymphoma and other difficult‑to‑treat cancers. Because the drug is still investigational, large‑scale, long‑term survival data are limited, and published reports mainly come from small or mid‑phase studies.

In a Phase II trial in relapsed PTCL, IV darinaparsin led to tumor shrinkage in many patients. Response rates were meaningful, with some patients achieving partial remission and others showing stable disease for several months. Disease progression was often slower than with prior therapies, particularly in patients who had already tried multiple regimens.

Studies in other hematologic cancers and solid tumors have also shown signs of clinical activity, including partial responses and disease stabilization in subsets of patients. However, outcomes vary widely based on cancer type, prior treatments, and how the arsenic pathway behaves in each person’s disease.

Safety Profile and Side Effects

As an arsenic‑derived agent, darinaparsin is still investigational and not yet labeled with a formal FDA Black Box Warning. However, clinicians closely monitor for neurologic, hematologic, and metabolic toxicities typical of arsenic‑based compounds.

Common side effects (>10%)

Fatigue or feeling unusually tired.
Nausea or vomiting.
Fever or chills, sometimes related to infusion or immune activation.
Dizziness or lightheadedness.

These effects are often mild to moderate and tend to improve with supportive care, rest, anti‑nausea medicines, and hydration.

Serious adverse events

Neurotoxicity: Mental status changes, confusion, ataxia (balance problems), or memory issues, which can be dose‑limiting at higher doses.
Speech or coordination problems, such as slurred speech or difficulty walking.
Rare neuropsychiatric effects, including agitation or hallucinations.
Possible hematologic toxicity, such as low blood counts, although this is less prominent than with classic chemotherapy.
Possible heart‑related changes or electrolyte disturbances in susceptible patients.

Management strategies

If neurotoxicity or confusion occurs, the infusion should be stopped and not resumed until symptoms resolve; the dose is often reduced in subsequent cycles.
Patients may receive premedication for nausea, such as anti‑nausea drugs, and should stay well hydrated during and after treatment.
Blood counts are monitored regularly; if counts drop significantly, treatment may be delayed or the dose reduced.
Any fever over 100.4°F (38°C), new confusion, severe dizziness, or major changes in coordination or speech should be reported immediately to the oncology team.
Most side effects are reversible with prompt care and dose adjustment, but long‑term neurologic follow‑up may be advised in patients who experience significant neurotoxicity.

Research Areas

Darinaparsin is being actively explored in combination therapies rather than as a stand‑alone agent. Current research focuses mainly on pairing it with other anticancer drugs or immunotherapies, especially in relapsed or refractory lymphomas.

Studies are testing darinaparsin together with checkpoint inhibitors and other immune‑modulating agents to enhance the body’s immune attack on tumors. The goal is to use arsenic‑induced stress and apoptosis as a way to make cancer cells more visible and vulnerable to immune‑directed therapies.

There is currently no strong evidence that darinaparsin is being used in combination with stem cell transplantation or classical regenerative medicine protocols. Its main role remains as an investigational arsenic‑based agent within oncology, with future research likely to focus on optimizing combinations and identifying biomarkers that predict who will benefit most.

Patient Management and Practical Recommendations

Because darinaparsin is still experimental, patients who receive it are typically enrolled in clinical trials at specialized cancer centers. Careful preparation, close monitoring, and clear communication between patients and the oncology team are essential for safety and to generate meaningful research data.

Pre‑treatment tests to be performed

Blood tests: Complete blood count (CBC), liver and kidney function, electrolytes, and markers of inflammation to assess baseline health.
Neurological exam: Assessment of baseline mental status, balance, coordination, and memory, especially in older patients or those with prior neurologic issues.
Electrocardiogram (ECG): To check heart rhythm and function, given the potential for arsenic‑related heart effects.
Imaging: CT, MRI, or PET scans to define tumor size, location, and stage before treatment.
Informed consent: Patients must fully understand that darinaparsin is investigational, review the potential benefits and risks, and sign a clinical‑trial consent form.

Precautions during treatment

Patients should attend all scheduled infusions and follow‑up visits, even if they feel well.
They should avoid driving or operating heavy machinery if they experience dizziness, confusion, or coordination problems.
Any new or worsening symptoms—such as fever, confusion, trouble walking, slurred speech, chest pain, shortness of breath, or severe fatigue—should be reported immediately.
Patients should stay well hydrated between cycles and follow good hygiene practices to reduce infection risk.

“Do’s and Don’ts” list

DO attend all monitoring visits, blood tests, and imaging studies as scheduled.
DO drink plenty of fluids and take prescribed anti‑nausea or anti‑fever medication as directed.
DO tell your oncologist before starting any new medicines, including over‑the‑counter drugs or supplements.
DON’T ignore fever over 100.4°F (38°C) or any new confusion, dizziness, or trouble walking; seek urgent medical care.
DON’T drive or handle heavy machinery if you feel dizzy, confused, or unsteady.
DON’T change the dose or schedule of darinaparsin without explicit medical advice.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice or a treatment recommendation. Darinaparsin is an investigational organic arsenical anticancer drug that is not currently approved by the U.S. Food and Drug Administration (FDA) for routine clinical use. It is available only through participation in approved clinical trials or special regulatory programs at qualified medical centers. Individual responses to darinaparsin may vary, and outcomes cannot be guaranteed.